ABSCIENCES (EPA:AB) | WebDisclosure

BRIEF

published on 12/17/2024 at 19:09, 3 days 20 hours ago

AB Science presents the advances of AB8939 for acute myeloid leukemia

Phase 1 AB8939 Acute Myeloid Leukemia Drug Resistance Potential Market
BRIEF

published on 12/17/2024 at 19:09, 3 days 20 hours ago

AB Science présente les avancées d'AB8939 pour la leucémie aiguë myéloïde

Phase 1 AB8939 Leucémie Myéloïde Aiguë Résistance Médicamenteuse Marché Potentiel
PRESS RELEASE

published on 12/17/2024 at 19:04, 3 days 21 hours ago

AB Science provides a summary of the webcast held on December 16, 2024
AB Science provides an update on AB8939, a novel microtubule destabilizer and ALDH inhibitor in phase 1 for AML treatment. Potential market size exceeded EUR 2 billion per annum

Market Potential AML Treatment AB Science Phase 1 AB8939
PRESS RELEASE

published on 12/17/2024 at 19:04, 3 days 21 hours ago

AB Science fournit un résumé de la conférence virtuelle qui s’est tenue le 16 décembre 2024
AB Science fait le point sur la molécule AB8939, un nouveau déstabilisateur de microtubules échappant à la résistance aux médicaments et inhibiteur de l’ALDH ciblant les cellules souches, actuellement en phase 1

Cellules Souches Traitement AB Science Leucémie AB8939
BRIEF

published on 10/17/2024 at 19:33, 2 months 3 days ago

AB Science Faces Setback in EMA Approval for ALS Treatment

AB Science Masitinib Marketing Authorization ALS Treatment EMA Decision
BRIEF

published on 10/17/2024 at 19:33, 2 months 3 days ago

AB Science fait face à un échec dans l'approbation par l'EMA du traitement de la SLA

Autorisation De Mise Sur Le Marché Masitinib Sciences AB Traitement De La SLA Décision De L'EMA
PRESS RELEASE

published on 10/17/2024 at 19:28, 2 months 3 days ago

AB Science fait le point sur la demande d'autorisation de mise sur le marché conditionnelle du masitinib dans la SLA
AB Science annonce un avis négatif de l'EMA sur la demande d'autorisation de mise sur le marché du masitinib pour la SLA malgré des résultats encourageants. La société se concentre sur l'étude confirmatoire

AB Science Masitinib Étude Confirmatoire EMA SLA
PRESS RELEASE

published on 10/17/2024 at 19:28, 2 months 3 days ago

AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science provides an update on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis. EMA confirms negative opinion but company remains focused on confirmatory phase 3 program

Phase 3 Program AB Science Masitinib Amyotrophic Lateral Sclerosis Conditional Marketing Authorisation
PRESS RELEASE

published on 10/11/2024 at 18:08, 2 months 9 days ago

Rapport financier semestriel 2024
PRESS RELEASE

published on 10/11/2024 at 18:01, 2 months 9 days ago

Rapport financier semestriel 2024

1 2 ... 4

Published on 12/21/2024 at 01:30, 14 hours 34 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 14 hours 34 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 15 hours 59 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 16 hours 4 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 16 hours 34 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 15 hours 12 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 15 hours 19 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 20 hours 53 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 21 hours 8 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 22 hours 4 minutes ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 3 hours 46 minutes ago

AXA annonce la signature d’un accord relatif à la vente d'AXA Investment Managers à BNP Paribas
Published on 12/21/2024 at 12:17, 3 hours 46 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 22 hours 4 minutes ago

Kapitaalverhoging door uitoefening van inschrijvingsrechten
Published on 12/20/2024 at 18:00, 22 hours 4 minutes ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 22 hours 9 minutes ago

Déclaration des transactions sur actions propres réalisées du 16/12/2024 au 20/12/2024

View all LES ECHOS COMFI WIRE

News